Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Short Interest Up 84.9% in August

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 12,218 shares, an increase of 84.9% from the August 15th total of 6,607 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Laboratorios Farmaceuticos Rovi Stock Performance

Shares of LABFF remained flat at C$67.17 during mid-day trading on Thursday. Laboratorios Farmaceuticos Rovi has a 1 year low of C$65.86 and a 1 year high of C$67.17. The business’s 50-day moving average price is C$66.44 and its two-hundred day moving average price is C$66.07.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.